Overview
GPE is a tripeptide, glycine-proline-glutamate, cleaved from the N-terminus of insulin-like growth factor 1. Its small size and derivation from a well-studied parent protein have made it a convenient research material for isolating neuroactive signaling from the broader IGF-1 pathway.
In preclinical models, GPE has been studied for its association with neuroprotective signaling independent of the classical IGF-1 receptor, in paradigms focused on neuronal survival. Researchers examining neurotrophic and neuroprotective mechanisms have used it as a research material for probing this fragment-level activity.
For a neurological catalog, GPE is notable as an example of how a fragment of a larger hormone can carry its own distinct research profile. Whether these mechanisms translate the same way across female physiology remains an open research question; our evidence review tracks how many of the underlying studies included women.
Summary
GPE (glycine-proline-glutamate) is an IGF-1-derived neuroprotective tripeptide studied preclinically for brain injury and neurodegeneration. GPE itself is preclinical, though a related analog, trofinetide, is FDA-approved for Rett syndrome; there is no female-specific evidence for GPE.
Evidence in women
Mechanism
An N-terminal cleavage product of IGF-1 proposed to have neuroprotective and neuromodulatory effects independent of the IGF-1 receptor.
Free research guide
How to tell real female data from male-extrapolated claims, with the questions to ask about any compound.
Citations (PMID)
Related peptides
Educational information for laboratory and research use only. Not medical advice, a recommendation, or a claim of safety or efficacy; no personal dosing. “Unstudied” means no qualifying study was found, not that a compound is safe or unsafe.